Company intelligence / Profile preview
AbVacc Inc.
Rockville, Maryland, United Statesabvacc.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
AbVacc has several candidates in advanced preclinical development with some entering clinical stage in the next few years. Their Staphylococcus aureus vaccine candidate has been licensed to LimmaTech Biologics for Phase 1 clinical development in 2024[2][3].
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- VaccinesMonoclonal antibodiesImmunotherapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
NIAIDCARB-XNovo Holdings Repair Impact FundEliteImmune Corp.Scripps Research InstituteLa Jolla Institute for ImmunologyViroVax LLCUniversity of Texas Medical BranchJohns Hopkins UniversityUniversity of RochesterUniversity of MarylandWashington UniversityIntegral MolecularLimmaTech Biologics
Beyond the preview
Go deeper on AbVacc Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbVacc Inc..